<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 17 Jun 2021 07:17:23 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>单抗注册生产现场检查中2个焦点问题和两大检查策略</title><link>https://mp.weixin.qq.com/s/Gg8aFHSeitXe5oTsv9SNxA</link><description></description><content:encoded><![CDATA[单抗注册生产现场检查中2个焦点问题和两大检查策略]]></content:encoded><pubDate>Wed, 16 Jun 2021 20:31:06 +0800</pubDate></item><item><title>深度：一文看懂中美I类新药审评差异</title><link>https://mp.weixin.qq.com/s/QjtQDN341O_uIG_TRCeALA</link><description></description><content:encoded><![CDATA[深度：一文看懂中美I类新药审评差异]]></content:encoded><pubDate>Wed, 16 Jun 2021 20:31:06 +0800</pubDate></item><item><title>基因治疗制品申报IND/NDA药学评价要点</title><link>https://mp.weixin.qq.com/s/Zo9rCNp0FnlTAEweNtUBtg</link><description></description><content:encoded><![CDATA[基因治疗制品申报IND/NDA药学评价要点]]></content:encoded><pubDate>Tue, 15 Jun 2021 20:54:51 +0800</pubDate></item><item><title>【CDE文献分享】| 创新单抗药物申报临床阶段药学研究关注点</title><link>https://mp.weixin.qq.com/s/vuY69PGzdfZ2g8HEgY6Omw</link><description></description><content:encoded><![CDATA[【CDE文献分享】| 创新单抗药物申报临床阶段药学研究关注点]]></content:encoded><pubDate>Tue, 15 Jun 2021 20:54:51 +0800</pubDate></item><item><title>注射剂一致性评价药学研究技术要求-PPT</title><link>https://mp.weixin.qq.com/s/WEjy9DZRWNrSu6q3DV8kQg</link><description></description><content:encoded><![CDATA[注射剂一致性评价药学研究技术要求-PPT]]></content:encoded><pubDate>Tue, 15 Jun 2021 20:54:51 +0800</pubDate></item><item><title>CDE老师文章｜国外药品审评专家咨询制度在药品审评体系中的作用及思考</title><link>https://mp.weixin.qq.com/s/tpaW0RvboPKqECw_gH1vRw</link><description></description><content:encoded><![CDATA[CDE老师文章｜国外药品审评专家咨询制度在药品审评体系中的作用及思考]]></content:encoded><pubDate>Mon, 14 Jun 2021 19:04:47 +0800</pubDate></item><item><title>药物共晶体和难溶性药物(一)</title><link>https://mp.weixin.qq.com/s/Vfj-u2-pnQCQy60RZfNDLQ</link><description></description><content:encoded><![CDATA[药物共晶体和难溶性药物(一)]]></content:encoded><pubDate>Mon, 14 Jun 2021 19:04:47 +0800</pubDate></item><item><title>2021大湾区变更解读会问答整理——《已上市化学药品和生物制品临床变更技术指导原则》（一）</title><link>https://mp.weixin.qq.com/s/UXy28XT_2Os7xci_UBrm2Q</link><description></description><content:encoded><![CDATA[2021大湾区变更解读会问答整理——《已上市化学药品和生物制品临床变更技术指导原则》（一）]]></content:encoded><pubDate>Mon, 14 Jun 2021 19:04:47 +0800</pubDate></item><item><title>创新单抗申报IND的8个药学要点</title><link>https://mp.weixin.qq.com/s/6JoEpqe3WsRK4X6pd7NruQ</link><description></description><content:encoded><![CDATA[创新单抗申报IND的8个药学要点]]></content:encoded><pubDate>Thu, 10 Jun 2021 20:14:16 +0800</pubDate></item><item><title>单抗申报IND 病毒安全性评价要点</title><link>https://mp.weixin.qq.com/s/xfsunlrRqzGqrZzish84yQ</link><description></description><content:encoded><![CDATA[单抗申报IND 病毒安全性评价要点]]></content:encoded><pubDate>Thu, 10 Jun 2021 20:14:16 +0800</pubDate></item><item><title>【干货】原料药工艺研发与控制QBD与质量风险管理</title><link>https://mp.weixin.qq.com/s/57XaGiTgYMxbTVt4BC7rSA</link><description></description><content:encoded><![CDATA[【干货】原料药工艺研发与控制QBD与质量风险管理]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:25:40 +0800</pubDate></item><item><title>CDE重磅发布《常见一般性技术问题130个解答》</title><link>https://mp.weixin.qq.com/s/Cv72narWjWEbpPIx0Kz_LQ</link><description></description><content:encoded><![CDATA[CDE重磅发布《常见一般性技术问题130个解答》]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:25:40 +0800</pubDate></item><item><title>辉瑞制药质量管理体系-PPT</title><link>https://mp.weixin.qq.com/s/fz0MVXW6dIOjUUSSohbPSQ</link><description></description><content:encoded><![CDATA[辉瑞制药质量管理体系-PPT]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:25:40 +0800</pubDate></item><item><title>乳腺癌大癌种：恒瑞CDK4/6即将上市，通用名已出！</title><link>https://mp.weixin.qq.com/s/I6qkLa1gAYFa3L3adUmfgA</link><description></description><content:encoded><![CDATA[乳腺癌大癌种：恒瑞CDK4/6即将上市，通用名已出！]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:25:40 +0800</pubDate></item><item><title>药品国际注册｜各国申报资料之差异</title><link>https://mp.weixin.qq.com/s/eFJft4ZW13ftizQeRFFeOw</link><description></description><content:encoded><![CDATA[药品国际注册｜各国申报资料之差异]]></content:encoded><pubDate>Tue, 08 Jun 2021 20:16:03 +0800</pubDate></item><item><title>肺癌靶向药物有哪些？及主要心血管毒性汇总</title><link>https://mp.weixin.qq.com/s/xde_7ZakdxWJeWKNBJDHxg</link><description></description><content:encoded><![CDATA[肺癌靶向药物有哪些？及主要心血管毒性汇总]]></content:encoded><pubDate>Tue, 08 Jun 2021 20:16:03 +0800</pubDate></item><item><title>全球首个延缓阿兹海默症进展新药获批上市，为何争议不断？</title><link>https://mp.weixin.qq.com/s/_nV-J8_PKN2iO0NNUqsWpA</link><description></description><content:encoded><![CDATA[全球首个延缓阿兹海默症进展新药获批上市，为何争议不断？]]></content:encoded><pubDate>Tue, 08 Jun 2021 20:16:03 +0800</pubDate></item><item><title>创新药物Ⅱ期临床研究设计的一般考虑</title><link>https://mp.weixin.qq.com/s/V6Tc9YfsOlaOAPgkQeGyEA</link><description></description><content:encoded><![CDATA[创新药物Ⅱ期临床研究设计的一般考虑]]></content:encoded><pubDate>Mon, 07 Jun 2021 20:07:12 +0800</pubDate></item><item><title>创新药物研发CMC阶段性研究深入探索</title><link>https://mp.weixin.qq.com/s/5eSGW7mifVOYRSOP-7QgLQ</link><description></description><content:encoded><![CDATA[创新药物研发CMC阶段性研究深入探索]]></content:encoded><pubDate>Mon, 07 Jun 2021 20:07:12 +0800</pubDate></item><item><title>超详细的生产现场问题</title><link>https://mp.weixin.qq.com/s/81AIUz-azAVNVADn-Qs8zQ</link><description></description><content:encoded><![CDATA[超详细的生产现场问题]]></content:encoded><pubDate>Mon, 07 Jun 2021 20:07:12 +0800</pubDate></item></channel></rss>